Abstract. Oleoyl-estrone (OE) decreases appetite, maintains energy expediture, induces lipolysis (sparing protein), and decreases cholesterolemia and insulin resistance. Rimonabant (SR141716) is a cannabinoid-receptor inhibitor that decreases appetite and mobilizes fat. We studied whether their combination improves their slimming effects. Male overweight rats received daily gavages of 5.3 mg / kg OE, 10 mg/ kg rimonabant, or both drugs during 10 days. Body weight and composition, energy balance, adipose tissue weight, and serum hormones and metabolites were measured. OE halved food intake and maintained energy expenditure at the expense of body fat. Rimonabant effects on appetite and energy balance were less marked, resulting in lower lipid mobilization. OE and rimonabant followed the OE pattern, with no additive or synergic effects. Glycemia was maintained, but OE decreased insulin, GLP-1, and cholesterol, whilst rimonabant increased cholecystokinin and cholesterol, and decreased NEFA. Both drugs decreased leptin and triacylglycerols; ghrelin was unchanged. The results hint at different mechanisms of action of both drugs: we can assume that OE effects do not involve the cannabinoid pathway. OE does not seem to act, either, after 10 days, through the secretion of ghrelin or the intestinal appetite-controlling peptides tested.
Introduction
Oleoyl-estrone (OE) is a natural hormone secreted by adipose tissue and carried by plasma lipoproteins (1) . Oral administration of OE results in a marked loss of body weight in rats (2) and humans (3) , characterized by a dose-dependent loss of body fat and the sparing of protein (4) ; this is achieved essentially by decreasing food intake and maintaining energy expenditure (5) . The powerful lipolytic effect of OE occurs in parallel to a decrease in overall glucose utilization (6) , maintenance of glycemia and liver glycogen (7) , and decrease of circulating insulin (and insulin resistance) and leptin (6 -8) . OE does not need the concurrence of dietary restrictions to induce the loss of body weight (9) . Rimonabant (SR141716), an inhibitor of the CB1 cannabinoid receptor (10) , has been found to markedly decrease appetite, both in rats (11) and humans (12) .
Treatment with rimonabant improves the handling of glucose (13) and decreases cardiovascular risk (14, 15) , by improving lipemia (16, 17) .
Both drugs share a marked effect on appetite, which results in the loss of body fat, and improve cardiovascular risk by decreasing the levels of circulating lipids. The combination of drugs for the treatment of obesity has been a widely extended practice in the past, in part because of the slow pace of weight loss and the usually limited overall effect, in spite of insufficient prior testing, with dramatically deleterious effects in some cases (18 -20) . OE has been found to produce in rats a synergic boosting of body fat loss both with a β 3 -adrenergic agent (21) and a serotoninergic drug, sibutramine (22) , indicating that its mechanism of action was complementary of both thermogenesis and inhibition of appetite by enhancement of postsynaptic serotonin activity. Combination of OE and dietary restriction, however, showed no improvement over the administration of OE alone in the handling of body fat, but OE markedly improved the body metabolic and hormonal environment when compared with restricted diet alone (9) .
This study was performed to determine whether the combination of OE and rimonabant may result in synergistic effects on body weight. In addition, the combination of both agents may help us determine whether OE actions in the control of appetite occur along the same path as rimonabant.
Materials and Methods
Male Wistar rats (Harlan-Interfauna, Sant Feliu de Codines, Spain), 45 days of age, were used. Rats were maintained under standard housing conditions in two-rat cages, and they were fed for five weeks a reduced cafeteria diet (21, 22) ad libitum. At the end of this phase, the animals were already overweight, that is, weighed 26% more than the same-age controls. This protocol resulted in the accumulation of 17% fat, compared with the normal 9% -11% fat content of a male rat this age and strain; the difference can be comparable to that of overweight versus normal-weight humans. The rats were re-conditioned during an additional week with standard rat chow ad libitum (maintenance chow; Panlab, Barcelona, Spain) as the sole food. They were used in the ensuing experiment at this point, when their age was 90 days, and they weighed 330 -390 g.
The experimental setup and procedures were approved by the Ethics Committee of the University of Barcelona. All animal handling procedures were carried out following the guidelines established by the EU and the Spanish and Catalan Governments.
All animals were maintained under standard conditions with full access to food pellets; their weights and food consumption were recorded daily. Five groups of six animals were randomly selected: a) zero-time controls, b) controls, c) oleoyl-estrone [OE], d) rimonabant [RI] , and e) rimonabant and oleoyl-estrone [RI-OE]. The rats in group a were killed and processed in order to obtain the proportions of body components at time zero. The remaining four groups received a daily gavage of 0.2 mL sunflower oil at the beginning of the light cycle. The gavage of rats in the control group contained only oil; rats in the OE and RI-OE groups gavage contained oleoyl-estrone (OED; Barcelona, Spain) at a daily dose of 10 µmol / kg (i.e. 5.34 mg / kg). In groups RI and RI-OE, the oil gavage also contained rimonabant (Pharma Chem Lansheng Corp., Shanghai, China) at a daily dose of 10 mg / kg.
The treatments continued for 10 days. At the end of the experiment, the rats were killed by decapitation. Blood was collected in dry beakers and allowed to clot. The serum was stored at −80°C until processed. The rats were dissected, and the stomach and intestinal contents were removed; the carcass and organs (including the unused blood and packed blood cells) were sealed in polyethylene bags, autoclaved, and thoroughly homogenized (4). The rat paste was used for the estimation of lipid (23) and energy content, using a bomb calorimeter (C-7000 Ika; Heitersheim, Germany). Paste composition was related to in vivo weight corrected by digestive canal contents. The absolute lipid and energy content of the rats at the beginning of the experiment was estimated by applying, to their known initial weights, the percentage body composition of the zero controls. The measured body weight and composition of the rats at the end of the study were used to determine the changes in body size and composition that occurred during the 10 days of treatment.
Energy intake was estimated from the food consumed, which contained a metabolizable energy of 13.3 kJ / g. Energy accrual was the difference between estimated energy on day 0 and the measured energy content (bomb calorimeter) on day 10. Mean energy expenditure was estimated as the difference between energy intake and net energy accrual.
Blood serum was used for the measurement of glucose (kit glucose PAP CP; Horiba ABX, Montpellier, France), non-esterified fatty acids (NEFA kit; Wako Chemicals, Neuss, Germany), 3-hydroxybutyrate (kit 907979; Roche, Mannheim, Germany), total triacylglycerols (kit 11528; Biosystems, Barcelona, Spain), total cholesterol (Cholesterol reagent easy; Menarini, Firenze, Italy), insulin (SRI-13K; Linco, St. Charles, MO, USA), ghrelin (kit RK-031031; Phoenix Europe Gmbh., Karlsruhe, Germany), cholecystokinin (kit RB-302; Euro-Diagnostics, Malmö, Sweden), and glucagonlike peptide 1 (GLP-1) (kit GLPIT-36HT, Linco).
Statistical comparisons between groups were established by two-way ANOVAs. Figure 1 shows the changes in body weight of overweight male rats treated with OE and rimonabant. OE induced a marked progressive loss of body weight, up to 13.8 ± 2.4% on day 10. Rimonabant rapidly decreased body weight on day 1, but practically went no further after the first days; on day 10, the overall loss of body weight was only 1.7 ± 0.4%. Combination of OE and rimonabant, resulted in intermediate effects between both extremes.
Results
Food intake is presented in Fig. 2 . OE reduced overall food intake by 55% in the 10-day period, whilst rimonabant decreased it only 23%; the combination of both compounds resulted in a 57% reduction. The patterns, however, were widely different, with OE effects being maximal on days 5 -7 forming a U-shaped curve, whilst rimonabant induced its maximal effects on food intake on day 1, and the gap between rimonabant and control rats progressively decreased thereafter. Combination of OE and rimonabant were, again, intermediate between both patterns, but nevertheless closer to that of the OEtreated rats. Table 1 shows the body composition of treated rats on day 10 compared with zero-time controls. Only OE Fig. 1 . Body weight change of overweight male Wistar rats receiving a daily oral dose of oleoyl-estrone and /or rimonabant. The data are the mean ± S.E.M. of six different animals and are expressed as percent of the initial body weight. Statistical significance of the differences between groups on day 10 (ANOVA): effect of oleoylestrone: P = 0.0000; effect of rimonabant: P = 0.6415 Fig. 2 . Food intake of overweight male Wistar rats receiving a daily oral dose of oleoyl-estrone and/or rimonabant. The data are the mean ± S.E.M. of six different animals. The statistical significance of the differences between groups with respect to the mean energy intake values for the whole period is presented in Fig. 3 . The data are the mean ± S.E.M. of six animals per group. BW, body weight; ±OE, plus /minus oleoyl-estrone in the gavage. Significance of the differences between groups (ANOVA): P values for the overall effects of OE (P OE) and rimonabant (P RI). *Statistically significance. There were no significant interactions between the different treatments (ANOVA).
reduced significantly body energy density and lipid content. Body energy increased 7.9 ± 4.9% in controls and decreased 30.8 ± 4.1% in OE, 3.3 ± 3.0% in rimonabant, and 30.0 ± 5.4% in OE combined with rimonabant. This loss was due essentially to a decrease in body lipids, which were practically halved in all OE-treated rats and decreased by 8.7% in those receiving only rimonabant. The loss of protein was only different from zero in the combined OE and rimonabant group, which lost 6.1%. The loss of energy was centered essentially on adipose tissue. Table 2 presents the wet weights of liver and a number of adipose tissue sites. OE induced a 15% decrease in liver weight, but there were no significant changes in the other groups. Interscapular brown adipose tissue (BAT) mass tended to decrease with OE, and to increase with rimonabant, but the changes were not statistically significant. OE decreased the mass of white adipose tissue (WAT) in all sites, but data on mesenteric and epididymal WAT were not statistically significant. Rimonabant effects were similar, but much less marked. The combination of OE and rimonabant induced more marked decreases in all WAT sites. Figure 3 shows the energy balance of the four groups of rats studied. Neither OE nor rimonabant or their combination affected energy expenditure. However, energy storage changed drastically from accrual of 20 ± 12% of energy intake in control rats to providing 53 ± 6%, 7 ± 5%, and 52 ± 6% of energy expenditure, respectively, for OE, rimonabant, and their combination, with the corresponding decreases in energy intake. Table 3 presents the serum composition of controls The data are the mean ± S.E.M. of six animals per group, and are expressed in g. BAT, brown adipose tissue; WAT, white adipose tissue; ±OE, plus /minus oleoyl-estrone in the gavage. Significance of the differences between groups (ANOVA): P values for the overall effects of OE (P OE) and rimonabant (P RI). *Statistically significance. There were no significant interactions between the different treatments (ANOVA). Fig. 3 . Energy balance of overweight male Wistar rats receiving a daily oral dose of oleoyl-estrone and / or rimonabant. Each experimental group is represented by two columns; the columns on the left represent the fate of the energy available (dotted = net energy stored and black = energy expenditure), and those on the right represent the source of that energy (white = net internal stores contribution and dashed = energy intake). All data were measured /calculated from six animals per group and are shown with the corresponding S.E.M. C = controls, RI = rimonabant, OE = oleoyl-estrone, OE + RI = combined OE and rimonabant. Statistical significance of the differences between groups (ANOVA): energy expenditure: effect of oleoyl-estrone: P = 0.1520, effect of rimonabant: P = 0.9407; energy intake: effect of oleoyl-estrone: P = 0.0000, effect of rimonabant: P = 0.0164; energy accrual: effect of oleoyl-estrone: P = 0.0238, effect of rimonabant: P = 0.3348. There were no statistically significant interactions between both treatments.
and rats treated with OE and rimonabant. There were no significant changes in glucose, in spite of a decrease in insulin in all OE groups. Non-esterified fatty acid levels did not change with respect to controls with OE, but rimonabant reduced their concentration. Triacylglycerol levels decreased in a similar way in all treated groups compared with controls. Cholesterol was markedly decreased by OE alone or in combination with rimonabant; the latter drug alone, however, increased cholesterol levels compared with controls. Leptin levels were reduced by rimonabant, but the decrease was more marked in OE-treated rats; in this case, the combination of both drugs resulted in a leptin level that was only 28% of the control value. Cholecystokinin levels were higher in rimonabant-treated rats and decreased with OE, but the differences of OE versus controls were not significant. Either OE or rimonabant did not change the levels of ghrelin. GLP-1 was unchanged by rimonabant alone, but OE, alone or combined, practically halved its levels.
Discussion
OE effects on weight, energy, lipid, and protein were similar to the previously reported ones (4, 9, 21, 22) . Rimonabant effects and its rapid effect on appetite agree with previous studies (11) . The effects of rimonabant on body fat content and on the distribution of fat in WAT sites were small, especially compared with OE.
The effects of the combination of OE and rimonabant on appetite were close to those of OE alone, body weight loss was: OE > OE + rimonabant > rimonabant; and fat loss in WAT was higher for the combination than for either drug alone. OE + rimonabant resulted in higher weight losses in WAT sites, but the overall body loss of lipids was similar to that of OE alone, which hints at the drug combination probably inducing the loss of fat in extra-WAT sites (such as muscle and liver). The higher weight loss of OE alone vs OE + rimonabant could not be simply justified by the loss of lipid or protein, and points to rimonabant inducing a higher retention of body water, in spite of cannabinoid receptor antagonists decreasing water intake along with diminished appetite (24) . The data are the mean ± S.E.M. of six animals per group. ±OE, plus/minus oleoyl-estrone in the gavage. Significance of the differences between groups (ANOVA): P values for the overall effects of OE (P OE) and rimonabant (P RI). *Statistically significance. There were significant interactions (ANOVA) between the treatments with OE and rimonabant only for triacylglycerols (P = 0.0031) and total cholesterol (P = 0.0085).
The lack of additive effects suggests that there are no grounds for their simultaneous administration: no synergistic effect was found in the combination for the purposes of shedding fat.
OE decreased circulating triacylglycerols and cholesterol in a similar proportion, but rimonabant tended to increase cholesterol whilst decreasing triacylglycerols, which suggest that OE (25, 26) and rimonabant (16, 17) are not coincident in the pathway to improve lipidemia, especially when OE levels of lipid went down under a massive peripheral lipolysis (4, 27) . These results partly contrast with the known effect of rimonabant increasing the HDL-cholesterol fraction and decreasing triacylglycerolemia in humans (28, 29) ; the difference with the present situation is probably a consequence of the different serum lipid handling by humans and rats. The improvement of insulin resistance was again more marked in OE-treated animals (6, 8, 30) , which maintained glucose levels and decreased circulating insulin.
The analysis of serum appetite-controlling peptides is not consistent in the case of OE with the observed decrease in appetite. Ghrelin has a powerful effect on hunger (31), thus increasing food intake (32) . OE or rimonabant did not change circulating ghrelin in spite of decreased food intake. GLP-1 tends to decrease appetite (33) , but this signal is also reduced in the rats receiving OE. Cholecystokinin enhances satiety by decreasing gastric emptying (34), a trait in part shared with OE (R. Ferrer-Lorente et al., unpublished results). Cholecystokinin is a well-known candidate for the pharmacological decrease of appetite (35) and has been found to act synergically with leptin in decreasing food intake (36, 37) . Rimonabant increased the levels of cholecystokinin, which was unaffected by OE.
The data on peptides suggests that OE does not act on appetite through inhibition of ghrelin secretion or enhancing the secretion of intestinal peptides that induce satiety or block food intake.
There was an additive effect of OE and rimonabant on leptin, both inducing decreases in leptin levels. Rimonabant decreases leptin, and endocannabinoids are controlled by leptin (38) . OE inhibits leptin synthesis and decreases its levels (7). The mechanism for this action is unclear, but in the case of OE, it seems to go beyond the decrease in WAT mass that obviously reduces the main site of leptin production (39) . The additive effects of rimonabant and OE are not directly related to the mass of adipose tissue and are probably the cause of different regulation paths acting on the secretion of leptin.
Leptin regulated the hypothalamic secretion of neuropeptide Y and proopiomelanocortins, controlling appetite (40, 41) , and its marked decrease may favor the action of orexigenic mechanisms. The low levels found here and the strongly inhibited food intake (at least in the OE-treated animals) do not agree with this function. OE has been found, however, to act on body fat and appetite downstream of leptin, since OE acts even on rats with compromised integrity in their leptinergic pathways (40) .
The lack of additive effects of OE and rimonabant on appetite and lipolytic activity, together with the different handling of lipids and intestinal peptides hint at different mechanisms of action of both drugs. Since rimonabant's mechanism of action is well known, blocking the CB1 cannabinoid receptors (10), we can assume that OE does not act through this cannabinoid pathway. OE does not seem to act, either, in the long term, through the control of ghrelin or intestine appetite-controlling peptides.
